Nutriband Inc. (NASDAQ:NTRB - Free Report) - Investment analysts at Noble Financial issued their FY2025 EPS estimates for Nutriband in a research note issued to investors on Wednesday, January 22nd. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of ($0.60) for the year. Noble Financial currently has a "Outperform" rating and a $13.00 target price on the stock. Noble Financial also issued estimates for Nutriband's Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.45 EPS and FY2028 earnings at $3.66 EPS.
Nutriband Stock Down 13.8 %
Shares of NTRB traded down $1.37 during trading hours on Friday, hitting $8.53. The company had a trading volume of 718,522 shares, compared to its average volume of 563,680. The stock has a market capitalization of $94.77 million, a price-to-earnings ratio of -12.01 and a beta of 0.99. The firm has a fifty day moving average price of $4.59 and a 200-day moving average price of $5.44. Nutriband has a 52-week low of $2.22 and a 52-week high of $11.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.83 and a current ratio of 4.96.
Nutriband (NASDAQ:NTRB - Get Free Report) last announced its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%.
Nutriband Company Profile
(
Get Free Report)
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Read More
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
